Reginald Oyortey

Reginald Oyortey

Auto-generated profile, based on publicly available information

Reginald Oyortey


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Journal of Case Reports in Medical Science
Verified
Journal Article
Closed access
UAUchechukwu Bethel Abioke
Uchechukwu Bethel Abioke
EOEnobong Edoabasi Obong
Enobong Edoabasi Obong
TATosin Abiodun Aderanti
Tosin Abiodun Aderanti
OJOlabode Olubunmi Joy
Olabode Olubunmi Joy
ROReginald Oyortey
Reginald Oyortey
Background: Herpes simplex encephalitis (HSE) is the most common cause of sporadic viral encephalitis. It typically presents with fever, seizures, and altered mental status. If untreated, mortality can reach 70%, and among survivors, 20–60% experience long-term cognitive or functional impairment. Case Study: A 49-year-old female with well-controlled hypertension presented with sudden quadriparesis and aphasia, initially raising concern for a cerebrovascular event. However, her course evolved atypically for stroke, with progressive confusion, seizures, and cognitive decline. MRI showed temporal lobe hyperintensities, and CSF PCR confirmed HSV-1 infection, establishing herpes simplex virus encephalitis. Following acute medical management, she received an eight-week structured physiotherapy and cognitive rehabilitation program. Interventions included gait and balance training, strengthening, and functional retraining. Outcome measures such as Mini-Mental State Examination (MMSE), Berg Balance Scale (BBS), Dynamic Gait Index (DGI), and Barthel Index (BI) demonstrated marked improvements in mobility, independence, and cognition. Conclusion: This case highlights the diagnostic challenge of HSE, which can mimic stroke and Parkinsonism, while also demonstrating the potential of structured physiotherapy to achieve meaningful functional and cognitive recovery. The co-occurrence of acute cognitive changes, motor deficits, and behavioral disturbances with temporal lobe MRI abnormalities should alert clinicians to this potentially treatable disease, particularly in regions with limited diagnostic resources.

6 January 2026 in Journal of Cancer and Tumor International
Verified
Journal Article
Closed access
ROReginald Oyortey
Reginald Oyortey
TATosin Abiodun Aderanti
Tosin Abiodun Aderanti
FNFaith Chinaza Ngwoke
Faith Chinaza Ngwoke
EOEsosa Omoregie
Esosa Omoregie
AAAnointing Akindele
Anointing Akindele
UAUchechukwu Bethel Abioke
Uchechukwu Bethel Abioke
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, driven largely by KRAS mutations and profound therapeutic resistance. This review summarizes recent translational strategies aimed at bridging laboratory discoveries with clinical application, including precision oncology, rational combination therapies, and stromal modulation. We examine preclinical and clinical studies that highlight mechanistic insights such as KRAS inhibition, PARP-targeted therapy, and multi-drug regimens, drawing lessons from genetically engineered mouse models, patient-derived xenografts, and biomarker-guided clinical trials. Recent advances demonstrate that previously undruggable targets, including KRAS, can now be modulated using mutation-specific inhibitors and combination therapies, achieving complete tumor regression in preclinical models. PARP inhibitors in BRCA-mutated PDAC exemplify the translation of precision medicine into patient benefit. Adaptive, biomarker-driven trials enhance the detection of therapeutic signals, while stromal reprogramming improves drug delivery and immune accessibility. Artificial intelligence and systems biology further support predictive modeling and optimization of trial design. Overall, translational research in PDAC shows that persistent mechanistic exploration, combination strategies, and innovative trial designs can overcome historical therapeutic barriers. Despite systemic challenges such as funding, regulatory hurdles, and structural limitations, these approaches provide a roadmap for improving clinical outcomes. Continued interdisciplinary collaboration and precision-guided interventions will be essential to fully realize the potential of these discoveries.